sitagliptin phosphate
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Non-Insulin-Dependent
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Trial Timeline
Apr 1, 2007 → Nov 19, 2009
NCT ID
NCT00545584About sitagliptin phosphate
sitagliptin phosphate is a phase 3 stage product being developed by Merck for Diabetes Mellitus, Non-Insulin-Dependent. The current trial status is completed. This product is registered under clinical trial identifier NCT00545584. Target conditions include Diabetes Mellitus, Non-Insulin-Dependent.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01512797 | Pre-clinical | Completed |
| NCT00833027 | Approved | Completed |
| NCT00642798 | Phase 1 | Completed |
| NCT00545584 | Phase 3 | Completed |
| NCT00832390 | Approved | Completed |
| NCT00696826 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Non-Insulin-Dependent